CG ONCOLOGY INC (CGON) Stock News
NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD
CGON Latest News, Press Relases and Analysis
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
Company News for May 14, 2025
Companies in The News Are: UAA,LSTR,SLAB,CGON
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -15.38% and 90.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ATRA
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates...
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Company News for Mar 31, 2025
Companies In The News Are: LULU, BRZE, AIR, CGON.
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of 45.45% and 6.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: YMAB
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: STOK
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
The companies are working on treatments for a form of bladder cancer.
Ashley McEvoy named Insulet CEO
McEvoy, the former leader of Johnson & Johnson’s medtech business, started immediately. Jim Hollingshead, who was CEO of Insulet for three years, resigned on Monday but will work as a consultant.
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at...
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025...
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates...
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy...
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates...
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presented